Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $41.9500 (-2.98%) ($41.9500 - $41.9500) on Mon. Mar. 8, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.38% (three month average) | RSI | 33 | Latest Price | $41.9500(-2.98%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.3% a day on average for past five trading days. | Weekly Trend | TGTX declines -3.7% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Rotation from growth to value for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(64%) ARKK(59%) IBB(59%) IWO(59%) | Factors Impacting TGTX price | TGTX will decline at least -3.19% in a week (0% probabilities). VIXM(-42%) VXX(-36%) UUP(-19%) UNG(-2%) TLT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.19% (StdDev 6.38%) | Hourly BBV | -0.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $32.09(-23.5%) | Inflection Point | Yes | Resistance Level | $45.71 | 5 Day Moving Average | $42.87(-2.15%) | 10 Day Moving Average | $43.6(-3.78%) | 20 Day Moving Average | $45.71(-8.23%) | To recent high | -23.4% | To recent low | 41.6% | Market Cap | $5.313b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |